Abstract |
Scabies is a disease in steady increase in Île-de-France region. Standard treatment, Ascabiol(®) ( benzyl benzoate/ sulfiram), is back-order for several months and its return remains uncertain. Facing this drug shortage, French Drug Agency (ANSM) has imported a drug from Germany, Antiscabiosum 10 % ( benzyl benzoate), to treat patients having contraindications for other scabicides available in France ( ivermectin, esdepallethrine). However, infants less than 1 year (<15 kg) and asthmatics infants have no alternative treatment. A multidisciplinary workgroup explored the various existing therapeutic alternatives in France and worldwide. From ANSM's recommendations and group's experience, a decision algorithm was proposed for treating patients. However, pediatric context implied the use of off-label drugs. Proposed treatments widely known by practitioners, prescriptions-types, dose, modalities of use and dispensation, and flyers to patients were realized to optimize treatment efficacy.
|
Authors | A Berthe-Aucejo, S Prot-Labarthe, L Pull, M Lorrot, S Touratier, H Trout, O Bourdon, L Dehen, E Bourrat |
Journal | Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
(Arch Pediatr)
Vol. 21
Issue 6
Pg. 670-5
(Jun 2014)
ISSN: 1769-664X [Electronic] France |
Vernacular Title | Traitement de la gale et rupture d'Ascabiol(®) : quid de la population pédiatrique ? Gale chez l'enfant et rupture d'Ascabiol(®) |
PMID | 24768069
(Publication Type: English Abstract, Journal Article)
|
Copyright | Copyright © 2014 Elsevier Masson SAS. All rights reserved. |
Chemical References |
- Benzoates
- Insecticides
- Permethrin
- Ivermectin
- benzyl benzoate
|
Topics |
- Benzoates
(supply & distribution, therapeutic use)
- Child
- Disinfection
- France
- Government Agencies
- Humans
- Insecticides
(supply & distribution, therapeutic use)
- Ivermectin
(therapeutic use)
- Permethrin
(therapeutic use)
- Scabies
(drug therapy)
|